about
Structural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: a combined in silico studyWhy CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritisEmerging concepts and approaches for chemokine-receptor drug discovery.Role of CCR2 in inflammatory conditions of the central nervous system.G protein-coupled receptors--recent advancesDiscovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 functionMast cells and company.CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone diseaseCCR6 as a possible therapeutic target in psoriasis.Functional inhibition of chemokine receptor CCR2 by dicer-substrate-siRNA prevents pain developmentInternational Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.CCR3 antagonists: a survey of the patent literature.Chemokines, neuronal-glial interactions, and central processing of neuropathic pain.Chemokines and chemokine receptors: new insights into cancer-related inflammation.Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases.N-aryl pyrazoles, indazoles and azaindazoles as antagonists of CC chemokine receptor 1: patent cooperation treaty applications WO2010/036632, WO2009/134666 and WO2009/137338.Small molecule HIV entry inhibitors: Part I. Chemokine receptor antagonists: 2004 - 2010.Targeting chemokine receptors in allergic disease.Novel C-C chemokine receptor 2 antagonists in metabolic disease: a review of recent developments.4-Azetidinyl-1-heteroatom linked cyclohexane antagonists of CCR2: patent evaluation.A dual CCR2/CCR5 chemokine antagonist, BMS-813160? Evaluation of WO2011046916.Mechanisms regulating chemokine receptor activity.Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation?Therapeutic potential of CCR1 antagonists for multiple myeloma.Therapeutic potential of chemokine receptor antagonists for liver disease.Progress in the discovery of CC chemokine receptor 2 antagonists, 2009 - 2012.Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4.CCR4 and its ligands: from bench to bedside.Peroxisome proliferator-activated receptor agonists modulate neuropathic pain: a link to chemokines?Analysis of patents on anti-rheumatoid arthritis therapies issued in China.CXCL12/CXCR4 axis: an emerging neuromodulator in pathological pain.The chemokines CCR1 and CCRL2 have a role in colorectal cancer liver metastasis.Identifying bias in CCR1 antagonists using radiolabelled binding, receptor internalization, β-arrestin translocation and chemotaxis assays.Internalization of CCR4 and inhibition of chemotaxis by K777, a potent and selective CCR4 antagonist.Chemokines in neuron-glial cell interaction and pathogenesis of neuropathic pain.Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist.Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist.Investigation of Inhibition Mechanism of Chemokine Receptor CCR5 by Micro-second Molecular Dynamics Simulations.In silico characterization of binding mode of CCR8 inhibitor: homology modeling, docking and membrane based MD simulation study.Insights into the binding modes of CC chemokine receptor 4 (CCR4) inhibitors: a combined approach involving homology modelling, docking, and molecular dynamics simulation studies.
P2860
Q28481687-A39F0BEE-3403-48E0-8CC1-64DB93B20194Q28742993-E9FB091A-9015-47D2-A350-94F72720B049Q33763369-7638A528-FFF7-4E0A-B898-6209922E0509Q34153471-D66D6DD8-7515-415A-9305-0934AE9251A1Q35065927-161C7054-90B7-4BC7-BA11-2F197DB1979FQ35588337-28EB0C20-267C-4F2F-AB53-FF442F6359ADQ35927793-28046ED2-F41D-42AD-9DDE-40106D43820AQ36177928-F921BD6A-039B-4125-A54D-EC2FDC7CAA42Q36980670-13746585-54F6-4818-9270-165058C72BD1Q37115195-82310512-24A3-4433-99A0-4F147AE9492EQ37432097-FB554137-ACF4-4DBA-8939-D8C616FAA016Q37564516-FC09539C-3D1A-48B3-A583-F012EDBACB2EQ37684327-7995C340-C5C3-4178-BDAA-D8897AD51BCBQ37694068-4A591BF2-B9A0-4712-ABD4-D98CFC3BE50BQ37723178-E654E746-E9E0-4191-B4C6-ECBBD118CCEDQ37790697-924052FA-71CB-4B27-9FD0-5473517C57A8Q37827167-9E79AF32-451A-4FCB-8E68-EB6979FC2779Q37832529-A2862F74-C7B4-4A86-9ECC-DB0A2AEA095CQ37861765-FCB8F747-9922-463D-8E2F-EB4C388C4481Q37873497-7DFE3C7E-FEEB-42DD-878D-8F8DEA42FE67Q37936463-EC9B73A8-65F1-4E1F-9195-483B4DFFC905Q37942973-57864F9F-64E6-48D8-8F8D-EC6FB8FEF05FQ37944472-8403A764-DC2D-433D-8D28-8A53C6EC287AQ37948866-31583341-87F6-415E-A75F-EBEF2AF2BB71Q37960533-94CE899E-BADD-4EF7-86F5-9C0079A8D431Q38083321-D5FF171B-76D4-4078-A781-F448BB5114C5Q38196934-F539A98F-9192-4362-8774-CED00D9941D8Q38236403-3C8B0C3B-2F57-4563-BAA6-608D9262C99EQ38246264-F002383C-75C8-4107-B9B7-01429B365734Q38525320-8F91876E-5B80-4DD4-AE47-4A70885A1EC8Q38583607-92AAE5AD-0DB2-45B5-9E04-F3327411E28DQ38834435-10C2B098-1682-4F88-B964-CAB099F44E5CQ38978556-2F106A80-FF10-4C3B-9B0D-F28AD768B948Q39141759-8F6C3560-08ED-4306-BD89-1779FA18A78EQ39227824-1DEECEF9-1012-4A3D-9B6D-AB039F62F4CAQ39514152-D42E462F-5121-4BB5-8F6B-241AAA9F43A3Q39514647-139B66D7-9489-4ACD-A159-63F18E5E3E2EQ41037672-9E3CD9DE-5537-444F-A78A-56ADD26208E5Q41533540-CB56D05B-CB62-4DD0-A853-EEA63BAEB0B5Q41728362-A510F163-0DF8-4F03-848F-9449E6A10CF5
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chemokine receptor antagonists: Part 1.
@en
Chemokine receptor antagonists: Part 1.
@nl
type
label
Chemokine receptor antagonists: Part 1.
@en
Chemokine receptor antagonists: Part 1.
@nl
prefLabel
Chemokine receptor antagonists: Part 1.
@en
Chemokine receptor antagonists: Part 1.
@nl
P2860
P1476
Chemokine receptor antagonists: Part 1.
@en
P2093
James E Pease
Richard Horuk
P2860
P356
10.1517/13543770802641346
P407
P577
2009-01-01T00:00:00Z